Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hikma Launches Dobutamine Injection, USP | Contract Pharma

What are you searching for?

Sign in
Breaking News

Hikma Launches Dobutamine Injection, USP

U.S. portfolio of sterile injectable medicines exceeds 150 products spanning a wide range of therapeutic areas and dosage forms.

By: Anthony Vecchione

Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, launched Dobutamine Injection, USP, in a 250mg/20mL vial in the US. With this launch, Hikma’s U.S. portfolio of sterile injectable medicines now exceeds 150 products spanning a wide range of therapeutic areas and dosage forms.

In addition, Hikma now markets approximately 30 sterile injectable medicines in Canada, with plans to launch up to 13 additional products this year. The company has also launched Hikma 503B, a new sterile compounding business focused on providing high-quality, ready-to-administer injectable medications that are customized to the specific needs of patients in the U.S.

“Our portfolio of more than 150 injectable medicines has expanded by more than 50 percent over the last three years, driven by customer needs, an expansion of our capabilities and product offerings, and the continued recognition of Hikma as a reliable, high-quality supplier of sterile injectable medicines,” said Riad Mishlawi, president, Injectables, Hikma. “As a top-three supplier of generic injectable medicines by volume in the US2, we are proud of the important role we play in the US health care system. We are committed to further growing our portfolio and capabilities and continuing to supply essential medicines to US hospitals, doctors, and patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics